Apremilast 30 mg Tablet

Aprezo 30 mg tablet contains apremilast 30 mg as the active ingredient. It is an oral tablet made by Glenmark. Each tablet is taken by mouth. It works through the bloodstream to reduce the immune activity causing visible skin damage.

Apremilast is a small molecule drug that works inside the immune cells to reduce inflammation. It belongs to a drug category called PDE4 inhibitors. The medicaton blocks specific enzyme, PDE4, which drives inflammatory signals. These signals are responsible for conditions like psoriasis and psoriatic arthritis. It works from the inside out. That is why dermatologists prescribe it when topical treatments alone are not enough.

Uses

Aprezo 30 mg tablet is used for plaque psoriasis. This is a chronic skin condition known for thick, scaly, red patches that appear on the scalp, elbows, knees, and lower back. It is also used for psoriatic arthritis. This affects people who have psoriasis and develop joint inflammation alongside their skin symptoms.

Psoriasis is not just cosmetic. It causes itching, cracking, and sometimes bleeding at the skin surface. Flares can be triggered by stress, certain medications, infections, or changes in weather.

How Apremilast Works on the Skin

PDE4 is an enzyme that keeps the inflammatory cycle running when active. Apremilast blocks PDE4. This reduces the production of pro-inflammatory signals inside the immune cells. With those signals reduced, the skin stops receiving the instructions that cause it to overproduce cells and inflame.

The result is less redness, less scaling, and thinner plaques over time. It does not suppress the whole immune system the way older biologics do. It targets a specific pathway. That makes it a useful option for people who need ongoing treatment.

How to Take Aprezo 30 mg Tablet

The standard course starts with a lower dose and increases over the first week. This helps reduce stomach side effects. By day six, the dose reaches 30 mg twice daily, taken morning and evening.

Swallow the tablet whole with water. It can be taken with or without food. Eating with the tablet during the first few weeks helps keep stomach discomfort manageable. Do not crush or split the tablet.

How Long Before the Skin Responds

Most people do not see a clear difference in the first two weeks. Noticeable improvement in plaque thickness and redness typically takes 4 to 16 weeks of consistent use.

Some patients ask at the 8-week mark whether it is working. It often is, just slowly. Give the full course its time.

Side Effects

Side effects are most noticeable in the first month and often reduce after that. Common ones include:

• Nausea
• Diarrhoea
• Headache
• Upper respiratory tract infections
• Stomach pain or discomfort
• Vomiting
• Fatigue
• Decreased appetite and weight loss with longer use

If you notice signs of depression, low mood, or unusual thoughts during the course, stop the drug and contact your doctor the same day.

Who Should Not Take Aprezo 30 mg Tablet

Do not take this tablet if you are pregnant. Apremilast has shown harmful effects in animal studies and should not be used during pregnancy. It should also not be taken by people with known hypersensitivity to apremilast or any ingredient in the tablet.

• Tell your doctor if you have a history of depression or thoughts of self-harm before starting.
• Avoid this tablet if you are taking rifampicin or similar drugs that strongly affect liver enzymes.
• Those drugs reduce how much apremilast the body absorbs.

Store at room temperature, away from moisture and direct sunlight. Keep out of reach of children.

• Many patients starting apremilast ask whether they can stop and restart if they miss several days.
• It is better to maintain the schedule.
• Stopping and restarting means going through the dose adjustment period again.
• That brings the stomach side effects back.

Price and Availability of Aprezo 30 mg Tablet

Aprezo 30 mg tablet is listed on Truedermo. The product is manufactured by Cipla. This apremilast 30 mg tablet is one option for long-term psoriasis treatment without moving directly to injectable biologics.